Navigation Links
Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Date:9/6/2007

ASHBURN, Va., Sept. 6 /PRNewswire/ -- Innocoll, Inc. announced that it has agreed the sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European sales and marketing infrastructure to EUSA Pharma Inc., a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care. The transaction provides EUSA with rights to Innocoll's GENTAMICIN SURGICAL IMPLANT, a biodegradable leave-behind surgical implant for the treatment and prevention of surgical site infections, for all worldwide markets except the US. Similar rights to Innocoll's two late stage development products, CollaRx GENTAMICIN TOPICAL for the treatment and prevention of diabetic foot infections and CollaRx BUPIVACAINE IMPLANT for the management of post-operative pain, were included as part of the transaction, together with an option to the US rights for the BUPIVACAINE IMPLANT. Innocoll will transfer to EUSA its pan-European sales and marketing infrastructure, which has a presence in over 20 European territories, as well as its distribution network covering more than 25 further countries around the world. Under the terms of the agreement, Innocoll will continue to manufacture and supply the products to EUSA and will progress the development of the late-stage clinical programs. In return, EUSA will make an upfront payment, pay development, regulatory and sales performance milestone fees and make an equity investment in Innocoll's parent company.

Commenting on the announcement, Dr. Michael Myers, President and CEO of Innocoll, Inc., said "In the relatively short time since acquiring the commercial rights to the Gentamicin Implant in 2005, we have successfully created a dedicated sales and marketing infrastructure and have seen substantial growth in product sales as a result. We believe EUSA is well positioned and fully committed to further build on the recent sales growth in Europe and expand into other international markets. Innocoll's products are an excellent
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
2. India and China Agrees to Promote Healthcare Jointly
3. China Agrees to Share Bird Flu Samples
4. Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin
5. New spray gel heals surgical wounds
6. FDA approves surgical gel
7. Sleep apnoea linked to surgical risks
8. Lower surgical volume linked to higher death rate
9. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
10. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
11. Indonesian boy with huge neck tumor was surgically removed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected patients ... treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, ... physicians at Wake Forest Baptist Medical Center. , ... experience with cytoreductive surgery and HIPEC, said lead ... 20 years, worth of patient data shows that ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... , SATURDAY, July 30 (HealthDay News) -- A new study ... users obsessively check their devices for e-mails, social media and ... the United States and Finland, and found that they checked ... less than 30 seconds and involves opening the screen lock ...
... , Alexandria, VA Tobacco related disease is a ... studies suggest that "alternative" tobacco products may have supplanted ... African Americans, according to new research published in the ... Neck Surgery. While the tobacco-related disease ...
... In an effort to reduce the radiation dose delivered by ... a comprehensive CT radiation dose reduction program which has allowed ... at their facility, according to an article in the August ... Radiology . CT is an essential tool ...
... approaches to dietary counseling for obesity are heavily rooted ... the ability to choose healthy foods and portion ... comfort foods. According to preventive medicine ... supports a new counseling approach that views obesity as ...
... FRIDAY, July 29 (HealthDay News) -- Any time there,s a ... at a youth camp in Norway, the shootings of a ... -- one question seems to ring clearer than others: Why ... disturbed and capable of committing deadly violence? Psychiatrists and ...
... , SATURDAY, July 30 (HealthDay News) -- Daughters have ... mothers, but there is no similar effect the other ... that teens may have more impact on their parents ... The study included 343 mother-daughter pairs who completed ...
Cached Medicine News:Health News:Smartphones Really Are Habit-Forming: Study 2Health News:Effects of tobacco use among rural African American young adult males 2Health News:Community hospital implements successful CT radiation dose reduction program 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 2Health News:Obesity counseling should focus on neurobehavioral processes, not personal choice, researchers say 3Health News:Shootings Spark Interest in Spotting the Violence-Prone 2Health News:Shootings Spark Interest in Spotting the Violence-Prone 3
(Date:1/14/2014)... Minn. , Jan. 14, 2014   NuAire , a manufacturer ... to agreement with Hitachi Koki of Japan ... in North America . NuAire will utilize its ... and Canada to offer assistance in ...
(Date:1/14/2014)... Inc. , a privately held company pioneering the development ... related neurodegenerative disorders, announced today the relocation of its ... as of January 15, 2014 and expanded lease agreement ... Oligomerix, which is focused on the development ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... and BEDMINSTER, N.J., Aug. 31 QRxPharma (ASX: QRX ... symposium at the 13th World Congress of Pain on ...  The symposium, titled "Dual Opioid Therapy: Changing the Paradigm" ... an immediate-release Dual Opioid product for moderate to severe ...
... plc (LSE: SHP, NASDAQ: SHPGY ), ... for inflammatory bowel disease (IBD) fellowships at leading medical ... in 2011 and will provide a year of training ... completed a fellowship in gastroenterology. "We are ...
Cached Medicine Technology:QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 2QRxPharma to Sponsor Symposium at 13th World Congress on Pain Meeting 3Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 2Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide 3
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: